Immunogenicity of Seven-Valent Pneumococcal Conjugate Vaccine Administered at 6, 14 and 40 Weeks of Age in South African Infants

Ítems similars

• Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants,
  per: Madhi, Shabir A., et al.
  Publicat: (2012)
• Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial
  per: Courtney P. Olwagen, et al.
  Publicat: (2024-12-01)
• Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status
  per: Madhi, Shabir A., et al.
  Publicat: (2017)
• Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study
  per: Alane Izu, et al.
  Publicat: (2025-12-01)
• Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial
  per: Madhi, Shabir A, et al.
  Publicat: (2020)